Physician profile
Michael Buxbaum
NPI 1023084159
$2,174.12
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $240 · 2021: $385 · 2022: $333 · 2023: $45.67 · 2024: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $259.28 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $257.72 | 2019 | |
| Alkermes, INC. | $227.76 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $183.91 | 2019-2021 | |
| Neos Therapeutics, LP | $163.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $122.23 | 2019-2023 | Xarelto |
| Lundbeck LLC | $115.41 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $98.02 | 2019-2022 | |
| Corium, LLC | $90.44 | 2022 | |
| Abbvie INC. | $70.13 | 2021 | |
| Tris Pharma INC | $69.01 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.65 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $55.16 | 2019 | |
| Ironshore Pharmaceuticals INC. | $45.97 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.53 | 2019-2020 | |
| Shire North American Group INC | $23.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.61 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.41 | 2019 | |
| Owp Pharmaceuticals, INC. | $14.21 | 2019 | |
| Adlon Therapeutics L.P. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Buxbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.